We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
+4.39%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.25B
AUM Growth
-$51.8M
Cap. Flow
+$301K
Cap. Flow %
0.02%
Top 10 Hldgs %
77.76%
Holding
39
New
4
Increased
7
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$13.6M
2
IMVT icon
Immunovant
IMVT
+$13.4M
3
EPIX
ESSA Pharma
EPIX
+$7.36M
4
MTEM
Molecular Templates, Inc.
MTEM
+$6.22M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$4.67M

Top Sells

Rank Stock Value
1
COLL icon
Collegium Pharmaceutical
COLL
+$18.9M
2
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$14.2M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$9.21M
4
CRDF icon
Cardiff Oncology
CRDF
+$3.34M
5
SPRY icon
ARS Pharmaceuticals
SPRY
+$1.66M

Sector Composition

Rank Sector Weight
1 Healthcare 98.78%
2 Miscellaneous 1.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FRLN
26
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$6.76M 0.54%
36,667
– –
EPZM
27
DELISTED
Epizyme, Inc
EPZM
$6.44M 0.52%
739,369
+7,933
+1% +$82.1K
AVDL
28
DELISTED
Avadel Pharmaceuticals
AVDL
$5.23M 0.42%
+578,104
New +$4.67M
BLU
29
DELISTED
BELLUS Health Inc.
BLU
$4.95M 0.4%
1,296,743
– –
ALNA
30
DELISTED
Allena Pharmaceuticals
ALNA
$4.63M 0.37%
3,330,373
– –
SRRA
31
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.49M 0.28%
202,803
– –
CRDF icon
32
Cardiff Oncology
CRDF
$76.7M
$2.72M 0.22%
293,500
-275,000
-48% -$3.34M
ITRM
33
DELISTED
Iterum Therapeutics
ITRM
$2.17M 0.17%
102,554
– –
GRTX
34
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$2.13M 0.17%
241,000
– –
NBRV
35
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$707K 0.06%
17,026
– –
COLL icon
36
Collegium Pharmaceutical
COLL
$820M
– –
-943,666
Closed -$18.9M
NERV icon
37
Minerva Neurosciences
NERV
$245M
– –
-7,693
Closed -$144K
RCKT icon
38
Rocket Pharmaceuticals
RCKT
$397M
– –
-168,000
Closed -$9.21M
SPRY icon
39
ARS Pharmaceuticals
SPRY
$600M
– –
-35,750
Closed -$1.66M
1
2

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q1 2021 Portfolio in Review

As of Q1 2021, Frazier Management held 39 positions worth $1.25B, down 4% from $1.3B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Frazier Management's Q1 2021 filing shows 4 new, 7 increased, 2 reduced and 4 closed positions. Its largest new stake was Aclaris Therapeutics: 696,000 shares worth $17.5M. The largest sale was Collegium Pharmaceutical, an estimated $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

  • Frazier Management's largest Q1 2021 buy was Aclaris Therapeutics: 696,000 shares worth $17.5M.
  • Frazier Management added most to Molecular Templates, Inc. in Q1 2021, an estimated $6.22M increase.
  • Frazier Management's biggest Q1 2021 reduction was Gritstone bio, Inc. Common Stock, cutting an estimated $14.2M.
  • Frazier Management fully exited Collegium Pharmaceutical in Q1 2021, selling an estimated $18.9M.
  • Frazier Management's ten largest holdings make up 78% of its $1.25B portfolio in Q1 2021.
  • Frazier Management opened 4 new positions and closed 4 in Q1 2021.
  • Frazier Management's portfolio value fell 4% quarter-over-quarter to $1.25B.

Based on Frazier Management's 13F filing for Q1 2021, filed 12 May 2021.